Complete Coverage
Median OS was significantly improved when dendritic cell vaccination therapy was added to standard second-line chemo in platinum-sensitive, relapsed ovarian cancer.
Concurrent surgery for cancer and stress urinary incontinence was associated with significantly improved QoL for women with early endometrial neoplasms and urinary stress incontinence.
According to researchers, responses to TSR-042 were seen in subgroups of patients with disease characterized as microsatellite instability (MSI)-high and MSI-low.
Median PFS was only 2.9 months for women with advanced cervical cancer receiving the combination of atezolizumab plus bevacizumab.
A clinical benefit rate of 86% was observed in a phase 2 trial of pembrolizumab plus chemotherapy in patients with recurrent, platinum-resistant ovarian cancer.
According to researchers, responses to tisotumab vedotin were seen in women with refractory advanced cervical cancer.
According to researchers, older age and black race were independent predictors of poor OS in women with stage I uterine leiomyosarcoma.
Single-agent neratinib was associated with durable responses in a subcohort of women in the SUMMIT trial.
High expression of indoleamine 2.3-dioxygenase pathway genes correlated with the presence of immune escape mechanisms in ovarian cancers, according to researchers.
The OS benefit of carboplatin desensitization was limited to the subgroup of women with recurrent ovarian cancer without deleterious germline BRCA1/2 mutations.
Researchers found that adjuvant chemoradiation therapy was preferable over adjuvant radiation therapy alone for squamous cell carcinoma of the vulva.
Researchers estimated cost effectiveness for first-line maintenance therapy with bevacizumab or olaparib in women with BRCA-mutant ovarian cancer.
Tumor response rates were higher in patients with platinum-sensitive recurrent ovarian cancers, according to researchers
According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.
According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.
Black women with locally advanced cervical cancer are significantly less likely to receive brachytherapy compared with non-black women with this disease.
In the QUADRA trial patients with low baseline platelet count or low body weight were more likely to experience grade 3/4 adverse events.
More data are needed regarding the efficacy and safety of administering multiple lines of PARP inhibitor therapy, according to researchers.
Simultaneous molecular characterization of paired germline and tumor specimens may gain importance as more targeted therapies become available.
Women aged 75 and older with advanced ovarian cancer enrolled in the phase 3 ARIEL3 trial were less likely to have deleterious germline or somatic BRCA mutations.
